**Table 1. Modified index of the Investigator’s Global Assessment scale to be used in the study**

|  |  |
| --- | --- |
| **IGA score** | **Description** |
| 0 | No skin rashes, no signs of inflammatory or non-inflammatory lesions |
| 1 | Minimal signs of the skin disease, less than 10–15% of the skin surface affected and/or few rashes, with minimal signs of inflammation |
| 2 | From >15 to 30% of the skin surface affected and/or significant rashes, moderate signs of inflammation |
| 3 | From 30 to 50% of the skin surface affected and/or smaller part of rashes with advanced signs of inflammation |
| 4 | More than 50% of the skin surface affected and/or most rashes with advanced inflammation |

IGA, Investigator’s Global Assessment scale

**Table 2. Changes of the Investigator’s Global Assessment score over time in the dermatological patients before and after SARS-CoV-2 infection**

|  |  |  |
| --- | --- | --- |
| **Group** | **IGA, Me [Q1; Q3]** | **P value p\*** |
| **Before SARS-CoV-2 infection** | **After SARS-CoV-2 infection** |
| 1 (n = 59) | 1.30 [1.0; 2.0] | 2.00 [2.0; 3.0] | < 0.001 |
| 2 (n = 181) | 2.00 [1.0; 2.0] | 3.00 [2.0; 3.5] | < 0.001 |
| 3 (n = 41) | 2.00 [1.0; 3.0] | 3.00 [2.0; 4.0] | 0.002 |
| 4 (n = 366) | 2.00 [2.0; 3.0] | 3.00 [3.0; 4.0] | < 0.001 |
| 5 (n = 177) | 2.00 [1.0; 2.5] | 3.00 [2.0; 3.5] | < 0.001 |
| 6 (n = 21) | 2.00 [1.0; 3.0] | 3.00 [2.5; 3.5] | 0.004 |
| P value | < 0.001\*\*p2–4 < 0.001p4–5 < 0.001p1–4 < 0.001 | < 0.001\*\*p2–4 < 0.001p4–5 = 0.003p1–4 < 0.001p1–5 = 0.010 | – |

IGA, Investigator’s Global Assessment scale; group 1, lichenoid pattern; group 2, eczematous pattern; group 3, bullous pattern; group 4, psoriatic pattern; group 5, fibrogenic pattern; group 6, granulomatous pattern

\* The significance of the within-group difference over time for the IGA score (Wilcoxon test)

\*\* The significance of the between-group difference over time for the IGA score (Kruskall-Wallis test)

**Table 3. Changes of the DLQI score over time in the dermatological patients before and after SARS-CoV-2 infection**

|  |  |  |
| --- | --- | --- |
| **Group** | **DLQI, Me [Q1; Q3]** | **P value p\*** |
| **Before SARS-CoV-2 infection** | **After SARS-CoV-2 infection** |
| 1 (n = 59) | 5.0 [3.0; 6.0] | 6.0 [4.75; 8.25] | < 0.001 |
| 2 (n = 181) | 6.5 [4.0; 10.5] | 13.0 [9.0; 17.0] | < 0.001 |
| 3 (n = 41) | 5.5 [3.0; 10.0] | 12.0 [6.0; 16.0] | < 0.001 |
| 4 (n = 366) | 8.0 [5.0; 12.0] | 14.0 [10.0; 18.88] | < 0.001 |
| 5 (n = 177) | 3.0 [1.0; 4.0] | 6.0 [4.0; 8.0] | < 0.001 |
| 6 (n = 21) | 4.5 [3.0; 6.0] | 7.5 [5.5; 11.5] | 0.006 |
| P value | < 0.001\*\*p3–5 = 0.001p2–5 < 0.001p1–2 = 0.001p4–5 < 0.001p4–6 = 0.029p1–4 < 0.001 | < 0.001\*\*p3–5 < 0.001p1–3 < 0.001p2–5 < 0.001p2–6 = 0.022p1–2 < 0.001p4–5 < 0.001p4–6 = 0.002p1–4 < 0.001 | – |

DLQI, Dermatology Life Quality Index; group 1, lichenoid pattern; group 2, eczematous pattern; group 3, bullous pattern; group 4, psoriatic pattern; group 5, fibrogenic pattern; group 6, granulomatous pattern

\* The significance of the within-group difference over time for the DLQI score (Wilcoxon test)

\*\* The significance of the between-group difference over time for the DLQI score (Kruskall-Wallis test)

**Table 4. The need of treatment modification in the in the dermatological patients after SARS-CoV-2 infection**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Previous treatment** |  | **Treatment modification** |
| **N** | **% [95% CI]** | **N** | **% [95% CI]** |
| 1 (n = 59) | 27 | 45.8 [32.7–59.2] | 32 | 54.2 [40.8–67.3] |
| 2 (n = 181) | 94 | 51.9 [44.4–59.4] | 87 | 48.1 [40.6–55.6] |
| 3 (n = 41) | 23 | 56.1 [39.7–71.5] | 18 | 43.9 [28.5–60.3] |
| 4 (n = 366) | 190 | 51.9 [46.7–57.1] | 176 | 48.1 [46.7–57.1] |
| 5 (n = 177) | 90 | 50.8 [43.2–58.4] | 87 | 49.2 [41.6–56.8] |
| 6 (n = 21) | 11 | 52.4 [29.8–74.3] | 10 | 47.6 [25.7–70.2] |

CI, confidence interval; group 1, lichenoid pattern; group 2, eczematous pattern; group 3, bullous pattern; group 4, psoriatic pattern; group 5, fibrogenic pattern; group 6, granulomatous pattern